Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin

British Journal of Cancer

Volumn 79, Issue 5-6, 1999, Pages 882-887

  De Jong, R S ^c   Mulder, N H ^c   Uges, D R A ^c   Sleijfer, D Th ^c   Hoppener F J P ^a   Groen, H J M ^c   Willemse, P H B ^c   Van Der Graaf, W T A ^c   De Vries, E G E ^b  

^a EORTC New Drug Development Office   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c NONE

Author keywords

Fostriecin; Pharmacokinetics; Phase I; Topoisomerase II

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; CREATININE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DRUG METABOLITE; FOSTRIECIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CREATININE BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERANCE; FATIGUE; FEVER; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; PRIORITY JOURNAL; SOLID TUMOR; ULTRAVIOLET RADIATION; VOMITING;

ADULT; AGED; ALANINE TRANSAMINASE; ALKENES; ANTIBIOTICS, ANTINEOPLASTIC; ASPARTATE AMINOTRANSFERASES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HALF-LIFE; HUMANS; LUNG NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PYRONES; TENIPOSIDE; TUMOR CELLS, CULTURED;

EID: 0000153936     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690141     Document Type: Article

References (20)

1. Beck WT and Danks MK (1991) Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Sem Cancer Biol 2: 235-244
2. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC and Fry DW (1988) Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 37: 4063-4068
3. Bouma P and Uges DRA (1980) Preparation of highly efficient columns for high-performance liquid chromatography. In: The Serum Concentration of Drugs, International Congress Series 501, Merkus FWHM (ed). pp 278-280. Excerpta Medica: Amsterdam
4. Clinical Brochure Fostriecin (1991) Bethesda, MD, USA, National Cancer Institute
5. Cummings J and Smyth JF (1993) DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 4: 533-543
6. De Jong S, Zijlstra JG, Mulder NH and De Vries EGE (1991) Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol 28: 461-464
7. De Jong RS, De Vries EGE, Meijer S, De Jong PE and Mulder NH (1998) Renal toxicity of the anticancer drug fostriecin. Cancer Chemother Pharmacol 42: 160-164
8. Froehlich-Ammon SJ and Osheroff N (1995) Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 270: 21429-21432
9. Fry DW, Besserer JA and Boritzki TJ (1984) Transport of the anti-tumour antibiotic CI-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res 44: 3366-3370
10. Guo XW, Thng JPH, Swank RA, Anderson HJ, Tudan C, Bradbury EM and Roberge M (1995) Chromosome condensation induced by fostriecin does not require p34(cdc2) kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation. EMBO J 14: 976-985
11. Leopold WR, Shillis JL, Mertus AE, Nelson JM, Roberts BJ and Jackson RC (1984) Anticancer activity of the structurally novel antibiotic CI-920 and its analogues. Cancer Res 44: 1928-1932
12. Osheroff N, Zechiedrich EL and Gale KC (1991) Catalytic function of DNA topoisomerase II. BioEssays 13: 269-275
13. Pillon L, Moore MJ and Thiessen JJ (1994) Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay. Ther Drug Monit 16: 186-190
14. Proost JH and Meijer DKF (1992) MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22: 155-160
15. Roberge M, Tudan C, Hung SM, Harder KW, Jirik FR and Anderson H (1994) Anti-tumour drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 54: 6115-6121
16. Scheithauer W, Von Hoff DD, Clark GM, Shillis JL and Elslager EF (1986) In vitro activity of the novel antitumour antibiotic fostriecin (CI-920) in a human tumour cloning assay. Eur J Cancer Clin Oncol 22: 921-926
17. Schilsky RL, Ramirez J, Wilson K, Vokes E, Kobayashi K, Berezin F, Wulff W and Ratain MJ (1994) Phase 1 clinical and pharmacological study of fostriecin in patients with advanced cancer. Proc Am Soc Clin Oncol 13: 321
18. Susick RL, Hawkins KL and Pegg DG (1990) Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in rats. Fundam Appl Toxicol 15: 258-269
19. Timmer-Bosscha H, Hospers GAP, Meijer C, Mulder NH, Muskiet FAJ, Martini IA, Uges DRA and De Vries EGE (1989) Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst 81: 1069-1075
20. 4. Br J Cancer 74: 1869-1876